Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly

被引:152
作者
Yamamoto, K
Takeshita, K
Kojima, T
Takamatsu, J
Saito, H
机构
[1] Nagoya Univ, Dept Transfus Med, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Dept Cardiol, Grad Sch Med, Nagoya, Aichi 4668550, Japan
[3] Nagoya Univ, Dept Med Technol, Sch Hlth Sci, Nagoya, Aichi 4668550, Japan
[4] Nagaya Med Ctr, Nagoya, Aichi 4668550, Japan
关键词
PAI-1; obesity; stress; immune response; vascular remodeling;
D O I
10.1016/j.cardiores.2004.11.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombotic cardiovascular diseases increase in incidence in the elderly, a tendency dependent on the age-related changes in vascular and hemostatic systems that include platelets, coagulation, and fibrinolytic factors as well as in the endothelium. The hypercoagulability of and advanced sclerotic changes in the vascular wall may contribute to the increased incidence of thrombosis in the elderly. One of the important key genes for aging-associated thrombosis is plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis. The expression of PAI-1 is not only elevated in the elderly but also significantly induced in a variety of pathologies associated with the process of aging. These conditions include obesity, insulin resistance, emotional stress, immune responses, and vascular sclerosis/remodeling. Several cytokines and hormones, including tumor necrosis factor-alpha, transforming growth factor-beta, angiotensin II, and insulin, positively regulate the gene expression of PAI-1. The recent epidemic in obesity with aging in the industrialized society may heighten the risk for thrombotic cardiovascular disease because adipose tissue is a primary source of PAI-1 and cytokines. Emotional or psychosocial stress and inflammation also cause the elevated expression of PAI-1 in an age-specific pattern. Thus, PAI-1 could play a key role in the progression of cardiovascular aging by promoting thrombosis and vascular (athero)sclerosis. Further studies on the genetic mechanism of aging-associated PAI-1 induction will be necessary to define the basis for cardiovascular aging in relation to thrombosis. (c) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:276 / 285
页数:10
相关论文
共 50 条
  • [1] Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis
    Alotaibi, Fahad T.
    Peng, Bo
    Klausen, Christian
    Lee, Anna F.
    Abdelkareem, Amr O.
    Orr, Natasha L.
    Noga, Heather
    Bedaiwy, Mohamed A.
    Yong, Paul J.
    PLOS ONE, 2019, 14 (07):
  • [2] Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
    Party, Helene
    Dujarrier, Cleo
    Hebert, Marie
    Lenoir, Sophie
    Martinez de Lizarrondo, Sara
    Delepee, Raphael
    Fauchon, Claudine
    Bouton, Marie-Christine
    Obiang, Pauline
    Godefroy, Olivier
    Save, Etienne
    Lecardeur, Laurent
    Chabry, Joelle
    Vivien, Denis
    Agin, Veronique
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2019, 7 (01)
  • [3] Murine plasminogen activator inhibitor-1 (PAI-1) does not affect adipogenesis or adipocyte differentiation
    Scroyen, I.
    Christiaens, V.
    Lijnen, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 : 160 - 160
  • [4] Glucocorticoid-Responsive Tissue Plasminogen Activator (tPA) and Its Inhibitor Plasminogen Activator Inhibitor-1 (PAI-1): Relevance in Stress-Related Psychiatric Disorders
    Mennesson, Marie
    Revest, Jean-Michel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [5] Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation
    Ma, Z.
    Paek, D.
    Oh, C. K.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (08) : 1136 - 1144
  • [6] Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke
    Chen, Rui
    Yan, Jinchuan
    Liu, Peijing
    Wang, Zhongqun
    Wang, Cuiping
    METABOLIC BRAIN DISEASE, 2017, 32 (03) : 667 - 673
  • [7] Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1)
    Morrow, Gael B.
    Mutch, Nicola J.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2023, 49 (03) : 305 - 313
  • [8] Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke
    Rui Chen
    Jinchuan Yan
    Peijing Liu
    Zhongqun Wang
    Cuiping Wang
    Metabolic Brain Disease, 2017, 32 : 667 - 673
  • [9] Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects
    Koistinen, HA
    Dusserre, E
    Ebeling, P
    Vallier, P
    Koivisto, VA
    Vidal, H
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2000, 16 (05) : 364 - 369
  • [10] Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss
    Mavri, A
    Alessi, MC
    Bastelica, D
    Geel-Georgelin, O
    Fina, F
    Sentocnik, JT
    Stegnar, M
    Juhan-Vague, I
    DIABETOLOGIA, 2001, 44 (11) : 2025 - 2031